Literature DB >> 36271029

Integrin regulation by tissue factor promotes cancer stemness and metastatic dissemination in breast cancer.

Betül Ünlü1, Begüm Kocatürk1, Araci M R Rondon1, Clayton S Lewis2, Nathalie Swier1, Rob F P van den Akker1, Danielle Krijgsman3, Iris Noordhoek3, Erik J Blok3, Vladimir Y Bogdanov2, Wolfram Ruf4,5, Peter J K Kuppen3, Henri H Versteeg6.   

Abstract

Tissue Factor (TF) is the initiator of blood coagulation but also functions as a signal transduction receptor. TF expression in breast cancer is associated with higher tumor grade, metastasis and poor survival. The role of TF signaling on the early phases of metastasis has never been addressed. Here, we show an association between TF expression and metastasis as well as cancer stemness in 574 breast cancer patients. In preclinical models, blockade of TF signaling inhibited metastasis tenfold independent of primary tumor growth. TF blockade caused a reduction in epithelial-to-mesenchymal-transition, cancer stemness and expression of the pro-metastatic markers Slug and SOX9 in several breast cancer cell lines and in ex vivo cultured tumor cells. Mechanistically, TF forms a complex with β1-integrin leading to inactivation of β1-integrin. Inhibition of TF signaling induces a shift in TF-binding from α3β1-integrin to α6β4 and dictates FAK recruitment, leading to reduced epithelial-to-mesenchymal-transition and tumor cell differentiation. In conclusion, TF signaling inhibition leads to reduced pro-metastatic transcriptional programs, and a subsequent integrin β1 and β4-dependent reduction in metastasic dissemination.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Year:  2022        PMID: 36271029     DOI: 10.1038/s41388-022-02511-7

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   8.756


  44 in total

Review 1.  Cancer stem cells: mirage or reality?

Authors:  Piyush B Gupta; Christine L Chaffer; Robert A Weinberg
Journal:  Nat Med       Date:  2009-09-04       Impact factor: 53.440

Review 2.  Breast cancer stem cells, EMT and therapeutic targets.

Authors:  Srishti Kotiyal; Susinjan Bhattacharya
Journal:  Biochem Biophys Res Commun       Date:  2014-09-26       Impact factor: 3.575

Review 3.  Molecular mechanisms of epithelial-mesenchymal transition.

Authors:  Samy Lamouille; Jian Xu; Rik Derynck
Journal:  Nat Rev Mol Cell Biol       Date:  2014-03       Impact factor: 94.444

Review 4.  EMT, CSCs, and drug resistance: the mechanistic link and clinical implications.

Authors:  Tsukasa Shibue; Robert A Weinberg
Journal:  Nat Rev Clin Oncol       Date:  2017-04-11       Impact factor: 66.675

5.  Cross-talk of integrin alpha3beta1 and tissue factor in cell migration.

Authors:  Andrea Dorfleutner; Edith Hintermann; Takehiko Tarui; Yoshikazu Takada; Wolfram Ruf
Journal:  Mol Biol Cell       Date:  2004-07-14       Impact factor: 4.138

6.  Inhibition of tissue factor signaling suppresses tumor growth.

Authors:  Henri H Versteeg; Florence Schaffner; Marjolein Kerver; Helle H Petersen; Jasimuddin Ahamed; Brunhilde Felding-Habermann; Yoshikazu Takada; Barbara M Mueller; Wolfram Ruf
Journal:  Blood       Date:  2007-09-27       Impact factor: 22.113

7.  Breast cancer statistics, 2017, racial disparity in mortality by state.

Authors:  Carol E DeSantis; Jiemin Ma; Ann Goding Sauer; Lisa A Newman; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-10-03       Impact factor: 508.702

Review 8.  Cancer stem cells and epithelial-mesenchymal transition: Novel therapeutic targets for cancer.

Authors:  Toshiyuki Ishiwata
Journal:  Pathol Int       Date:  2016-08-10       Impact factor: 2.534

9.  Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis.

Authors:  Myriam Labelle; Shahinoor Begum; Richard O Hynes
Journal:  Cancer Cell       Date:  2011-11-15       Impact factor: 31.743

10.  Tissue Factor promotes breast cancer stem cell activity in vitro.

Authors:  Hudhaifah Shaker; Hannah Harrison; Robert Clarke; Goran Landberg; Nigel J Bundred; Henri H Versteeg; Cliona C Kirwan
Journal:  Oncotarget       Date:  2017-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.